Astellas Pharma Stock Price, News & Analysis

Astellas (ALPMY) has announced its second annual Patient Advocacy Organization (PAO) Action Week™, scheduled for June 9-13, 2025. The initiative, coordinated by Astellas' Patient Centricity team volunteers, aims to connect patients and caregivers with essential resources from over 1,200 PAOs in the U.S. Following the successful inaugural event in 2024, this year's campaign focuses on raising awareness about PAOs' crucial role in providing disease education, support groups, and advocacy for treatment access and research funding.

The event brings together life sciences companies, healthcare organizations, and patient advocacy groups to enhance awareness and accessibility of PAO resources. Organizations can register to participate through the PAO Action Week website (paoactionweek.com/join-us), and stakeholders can follow the campaign through #PAOActionWeek on social media.

Astellas Pharma (ALPMY) and MBC BioLabs have announced DeepSeq.AI and Serna Bio as the winners of the 2025 Astellas Future Innovator Prize. Selected from over 50 applications, both companies will receive one-year priority access to MBC BioLabs' state-of-the-art facility in San Francisco, along with access to Astellas' R&D capabilities and business expertise.

The winners were chosen based on their innovative approaches, therapeutic potential, and platform scalability. DeepSeq.AI focuses on oncology and infectious diseases, while Serna Bio specializes in CNS research. This marks the sixth year of the award program, which aims to support early-stage life-science companies in advancing their research into viable treatments.

For XTANDI (enzalutamide): New post hoc analyses of long-term overall survival data, including the ARCHES five-year follow-up OS analysis in metastatic hormone-sensitive prostate cancer patients. The ENZAMET trial will present eight-year data comparing enzalutamide vs non-steroidal anti-androgen.

For PADCEV (enfortumab vedotin): Two analyses from the phase 3 EV-302 study in previously untreated locally advanced or metastatic urothelial carcinoma, featuring an exploratory analysis of responders and long-term subgroup analysis.

The presentations emphasize Astellas' focus on long-term overall survival data and clinical outcomes that matter to patients in advanced prostate and bladder cancers.

Astellas Pharma (ALPMY) and YASKAWA Electric have signed a definitive agreement to establish a joint venture focused on developing a cell therapy manufacturing platform using YASKAWA's dual-arm robot 'Maholo'. The collaboration aims to address key challenges in cell therapy commercialization, particularly regarding manufacturing accuracy and reproducibility.

The joint venture will combine Astellas' expertise in cell therapy R&D and manufacturing with YASKAWA's robotic technology. The platform will be made accessible to startups and academic institutions to foster innovation in cell therapy development. The initiative addresses industry-wide challenges including the need for skilled workforce and complex technology transfer requirements.

The establishment of the joint venture, following a May 2024 memorandum of agreement, is subject to regulatory approvals and other closing conditions.

Astellas Pharma and MBC BioLabs have announced their sixth annual Astellas Future Innovator Prize competition. The prize offers emerging biotech startups and entrepreneurial scientists one year of priority access to MBC BioLabs' advanced Bay Area facilities, along with access to Astellas' R&D capabilities and business expertise.

The initiative aims to accelerate early drug discovery and research efforts, supporting the development of novel therapeutic programs, modalities, and platforms. Last year's winners were Tipping Point Biosciences and Altay Therapeutics, selected for their potential to address unmet medical needs.

Interested participants have until April 1, 2025 to submit their non-confidential company presentations, including a one-page executive summary.